May 22, 2025 Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial Read more
May 15, 2025 Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience Read more
January 21, 2025 Rubedo Life Sciences Announces Clinical Development Plans for Lead Candidate RLS-1496, a First-in-Class GPX4 Modulator Targeting Aging Cells and Surrounding Tissues Read more
December 18, 2024 Rubedo Life Sciences Appoints Former Allergan Executive and Biotechnology Veteran Dr. Frederick Beddingfield III as CEO Read more
October 23, 2024 Rubedo Life Sciences Announces European Expansion Ahead of First Clinical Trial Read more
April 23, 2024 Rubedo Life Sciences and Beiersdorf Announce Multi-Year Partnership to Pioneer New Skin Care Products that Address Cellular Aging Read more
April 22, 2024 Rubedo pulls in $40M Series A to advance atopic dermatitis candidate targeting aging cells Read more
April 22, 2024 Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital Read more
May 4, 2023 Rubedo Life Sciences Announces Nomination of First-in-Class Disease-Modifying Candidate RLS-1496 in Dermatology at LSX World Congress 2023 Read more
March 20, 2023 Rubedo Life Sciences Presents In Vivo Efficacy Data Targeting Senescence Cells to Treat Dermatological Diseases Read more
February 10, 2023 RUBEDO receives $1.45M award from California Institute for Regenerative Medicine (CIRM) to advance its age-related pulmonary fibrosis program Read more
October 28, 2020 Another New Senolytic Prodrug is Demonstrated to Reverse Frailty and Loss of Cognitive Function in Old Mice Read more
November 13, 2018 The anti-ageing compound: Scientists create a chemical that can restore hair and give youthful energy Read more
